负荷后2小时血糖与色素上皮衍生因子是2型糖尿病患者冠状动脉炎症的标志物
本研究纳入38例已接受口服降糖药(除吡格列酮外)的2型糖尿病合并颈动脉粥样硬化患者,在加用吡格列酮或格列美脲治疗4个月前后进行75g口服葡萄糖耐量试验、血液生化分析和FDG-PET/CT。结果显示加药治疗后空腹血糖、负荷后30/60/90/120分钟血糖、HbA1c及左主干冠状动脉靶本比(LMT-TBR)显著降低,而高密度脂蛋白胆固醇和脂联素升高;基线PEDF升高和未使用阿司匹林可预测LMT-TBR的有利反应,Δ120分钟负荷后血糖和ΔPEDF是ΔLMT-TBR的独立相关因素。结论提示负荷后120分钟血糖和PEDF值可能是2型糖尿病患者冠状动脉炎症的标志物和潜在治疗靶点。
要点
- 加用吡格列酮或格列美脲4个月可显著降低2型糖尿病患者的LMT-TBR。
- 基线PEDF升高和未使用阿司匹林可预测LMT-TBR对加药治疗的有利反应。
- Δ120分钟负荷后血糖和ΔPEDF是ΔLMT-TBR的独立相关因素。
核心结论
- 负荷后120分钟血糖和PEDF值可能是2型糖尿病患者冠状动脉炎症的标志物和潜在治疗靶点。
研究设计与样本
- 研究纳入38例已接受除吡格列酮外口服降糖药的2型糖尿病合并颈动脉粥样硬化患者。
- 在基线及加用吡格列酮或格列美脲治疗4个月后,所有患者接受75g口服葡萄糖耐量试验、血液生化分析和FDG-PET/CT。
主要发现
- 加药治疗后空腹血糖、负荷后30、60、90、120分钟血糖、HbA1c及LMT-TBR值显著降低。
- 加药治疗后高密度脂蛋白胆固醇和脂联素水平升高。
- 基线血清PEDF升高和未使用阿司匹林可预测LMT-TBR对加药治疗的有利反应。
- Δ120分钟负荷后血糖和ΔPEDF是ΔLMT-TBR的独立相关因素。
关键数值与推荐
- 基线PEDF升高和未使用阿司匹林可预测LMT-TBR的有利反应。
- Δ120分钟负荷后血糖和ΔPEDF是ΔLMT-TBR的独立相关因素。
临床怎么用
- 在2型糖尿病患者中,可关注负荷后120分钟血糖和PEDF水平以评估冠状动脉炎症风险。
- 负荷后120分钟血糖和PEDF或可作为冠状动脉炎症的潜在治疗靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We have previously found that pioglitazone attenuates inflammation in the left main trunk of coronary artery (LMT), evaluated as target-to-background ratio (TBR) by 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in patients with impaired glucose tolerance or type 2 diabetes. OBJECTIVES: We assessed which clinical variables could predict the change in TBR in the LMT after 4-month add-on therapy with oral hypoglycemic agents (OHAs). METHODS: A total of 38 type 2 diabetic patients with carotid atherosclerosis who had already received OHAs except for pioglitazone was enrolled. At baseline and 4 months after add-on therapy with pioglitazone or glimepiride, all patients underwent 75 g oral glucose tolerance test, blood chemistry analysis, and FDG-PET/CT. RESULTS: Fasting plasma glucose, 30-, 60-, 90-, 120-minutes postload plasma glucose, HbA1c, and LMT-TBR values were significantly decreased by add-on therapy, whereas high-density lipoprotein-cholesterol and adiponectin levels were increased. Increased serum levels of pigment epithelium-derived factor (PEDF), a marker of insulin resistance and non-use of aspirin at baseline could predict the favorable response of LMT-TBR to add-on therapy. Moreover, Δ120-minutes postload plasma glucose and ΔPEDF were independent correlates of ΔLMT-TBR. CONCLUSIONS: Our present study suggests that 120-minutes postload plasma glucose and PEDF values may be markers and potential therapeutic targets of coronary artery inflammation in type 2 diabetic patients. CLINICAL TRIAL REGISTRATION: URL: http://clinicaltrials.gov . Unique identifier: NCT00722631. New markers for diabetes and CAD is on the horizon! Two-hour postload plasma glucose and pigment epithelium derived factor are markers of coronary artery inflammation in type 2 diabetic patients.
引用
- Tahara N, Nitta Y, Bekki M, et al. Two-hour postload plasma glucose and pigment epithelium-derived factor levels are markers of coronary artery inflammation in type 2 diabetic patients. J Nucl Cardiol. 2019. PMID: 31407236. doi:10.1007/s12350-019-01842-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。